{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05308264",
            "orgStudyIdInfo": {
                "id": "C-906289-002"
            },
            "organization": {
                "fullName": "Rigel Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)",
            "officialTitle": "An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Refractory/Resistant to Prior Therapies",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "study-of-in-participants-with-lower-risk-myelodysplastic-syndromes-lr-mds"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2022-09-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-02",
            "studyFirstSubmitQcDate": "2022-03-25",
            "studyFirstPostDateStruct": {
                "date": "2022-04-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-06",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Rigel Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Phase 1b Study of R289 in Participants with Lower-risk Myelodysplastic Syndromes (LR MDS)",
            "detailedDescription": "An open-label, Phase 1b study of R289 to determine tolerability and preliminary efficacy in participants with LR MDS who are relapsed, refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS."
        },
        "conditionsModule": {
            "conditions": [
                "Low Risk Myelodysplastic Syndromes"
            ],
            "keywords": [
                "MDS",
                "LR MDS",
                "Myelodysplastic Syndromes",
                "Hematology Oncology",
                "Hem/ Onc"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 34,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Experimental",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd and 1000 mg PO qd",
                    "interventionNames": [
                        "Drug: R906289 Monosodium (R289 Na)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "R906289 Monosodium (R289 Na)",
                    "description": "Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd,500 mg PO qd, 750 mg PO qd, 1000 mg PO qd)",
                    "armGroupLabels": [
                        "Experimental"
                    ],
                    "otherNames": [
                        "R906289 Monosodium"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and Tolerability",
                    "description": "* Incidence of adverse events (AEs)\n* Incidence of discontinuation or interruptions of R289 due to AEs\n* Incidence of dose limiting toxicities (DLTs)",
                    "timeFrame": "2 Year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Participants with red blood cell transfusion independence by Week 24",
                    "description": "Proportion of participants who achieve \u2265 50% reduction in number of red blood transfusion compared to baseline and \u2265 24 weeks.",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Characterize pharmacokinetics (PK)",
                    "description": "Maximum plasma concentration (Cmax)",
                    "timeFrame": "8 Weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Characterize pharmacodynamic (PD)",
                    "description": "Change from baseline biomarker expression levels in plasma and bone marrow (including but not limited to, C-reactive protein \\[CRP\\] and tumor necrosis factor \\[TNF\\]-a)",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be \u2265 18 years of age at the time of signing the informed consent.\n* Must have definitive diagnosis of MDS with very low, low, or intermediate-1 risk (International Prognostic Scoring System (IPSS)-R \u2264 3.5) and \u22645% bone marrow myeloblasts.\n* Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as TPOs, EPOs, luspatercept, and HMAs(i.e., azacytidine or decitabine). Participants with del (5q) must have failed prior lenalidomide therapy.\n* Must be blood transfusion dependent and meet at least one of the disease-related criteria for RBC transfusion, or platelet count within 8 weeks prior to initial administration of study treatment:\n\n  1. Symptomatic anemia untransfused with hemoglobin \\< 9.0 g/dL within 8 weeks of registration or red blood cell (RBC) transfusion dependent defined as receiving \u2265 2 units of packed red blood cells (PRBCs) within 8 weeks in the preceding 16 weeks for a hemoglobin \\<9.0 g/dL.\n  2. Clinically relevant thrombocytopenia (platelet counts of \\<100 \u00d7 109/L in at least 2 blood counts prior to study treatment and transfusion dependence).\n\nAll participants must have documented marrow iron stores. If marrow iron stain is not available, the transferrin saturation must be \\>20% or a serum ferritin \\> 100ng/100mL\n\n* Must have Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 at screening.\n* Must have adequate organ function, defined as:\n\n  1. Hepatic function:\n\n     * aspartate amino transferase (AST) or alanine aminotransferase (ALT) \u2264 1.5 \u00d7 upper limit of normal (ULN)\n     * total bilirubin \u2264 1.5 \u00d7 ULN\n  2. Renal function defined as creatinine clearance \\> 60 mL/min (using Cockcroft-Gault), or blood creatine \\< 1.5 mg/dL\n\nExclusion Criteria:\n\n* Prior treatment for MDS (i.e., TPOs, EPOs, luspatercept, HMAs) concluded \\< 4 weeks prior to study treatment\n* Clinically significant anemia resulting from iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis, or GI bleeding.\n* MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases.\n* Diagnosis of chronic myelomonocytic leukemia.\n* History of uncontrolled seizures.\n* Uncontrolled bacterial or viral infection (i.e., documented HIV, hepatitis B or hepatitis C).\n* History of an active malignancy within the past 2 years prior to study entry, with the exception of:\n\n  1. Adequately treated in situ carcinoma of the cervix uteri\n  2. Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin, or\n  3. Any other malignancy with a life expectancy of more than 2 years\n* History of or active, clinically significant, cardiovascular, respiratory, GI, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator's opinion, could affect the conduct of the study or the absorption, metabolism or excretion of the study treatment.\n* Prior history of bone marrow transplantation.\n* Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \\> 480 milliseconds \\[msec\\]) (Common Terminology Criteria for Adverse Events \\[CTCAE\\] Grade 1) using Fridericia's QT correction formula.\n* History of additional risk factors for TdP (e.g., symptomatic heart failure with left ventricular ejection fraction \\[LVEF\\] \\<40%, hypokalemia, family history of Long QT Syndrome).\n* Receiving any other concurrent chemotherapy, radiotherapy, or immunotherapy (within 2 weeks of initiating study treatment), or the toxicity of the relevant prior treatment has not been resolved yet.\n* Use of concomitant medications that prolong the QT/QTc interval during study treatment\n* Use of concomitant medications that are strong CYP3A or CYP2B6 inhibitors or inducers during study treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Elizabeth Franklin",
                    "role": "CONTACT",
                    "phone": "(650) 624-1100",
                    "email": "clinicaltrials@rigel.com"
                },
                {
                    "name": "Donna Chow",
                    "role": "CONTACT",
                    "phone": "(650) 624-1100",
                    "email": "clinicaltrials@rigel.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "Mount Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Miami Beach",
                    "state": "Florida",
                    "zip": "33140",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.79065,
                        "lon": -80.13005
                    }
                },
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Hackensack University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Rutgers Cancer Institute of New Jersey",
                    "status": "WITHDRAWN",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "09083",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Ichan School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "University of Texas, Southwestern",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}